Compare NEXN & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEXN | PACB |
|---|---|---|
| Founded | 2007 | 2000 |
| Country | Israel | United States |
| Employees | 909 | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Laboratory Analytical Instruments |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 411.2M | 459.0M |
| IPO Year | N/A | 2010 |
| Metric | NEXN | PACB |
|---|---|---|
| Price | $6.60 | $1.38 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $11.69 | $2.10 |
| AVG Volume (30 Days) | 339.9K | ★ 4.9M |
| Earning Date | 03-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $93,468,000.00 |
| Revenue This Year | N/A | $11.22 |
| Revenue Next Year | N/A | $12.41 |
| P/E Ratio | $9.64 | ★ N/A |
| Revenue Growth | N/A | ★ 3.04 |
| 52 Week Low | $5.60 | $0.85 |
| 52 Week High | $12.00 | $2.73 |
| Indicator | NEXN | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 46.77 | 38.79 |
| Support Level | $6.28 | $1.36 |
| Resistance Level | $6.85 | $1.51 |
| Average True Range (ATR) | 0.35 | 0.09 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 28.29 | 29.07 |
Nexxen International Ltd is a globalized and flexible advertising technology platform with deep expertise in data and advanced TV that helps empower advertisers, agencies, digital publishers and broadcasters to achieve desired outcomes, including increased efficiency and returns, across the media supply chain. It is a demand-side platform (DSP), supply-side platform (SSP), ad server, and data management platform (DMP) and also delivers a flexible and unified technology stack with and exclusive data at its core. Company operates in America, APAC, EMEA, regions, with majority revenue from America.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.